摘要目的 探讨肝细胞肝癌(HCC)患者血清甲胎蛋白-IgM免疫复合物(AFP-IgM)的表达水平及其临床意义.方法 应用酶联免疫吸附分析(ELISA)法检测79例HCC患者、20例中度肝硬化患者和30例健康对照者血清中AFP-IgM水平,并进行对比分析.结果 AFP-IgM的浓度和阳性率分别为HCC组422.20×103AU/L和73%,肝硬化组268.85×103AU/L和20%,健康对照组119.71×103AU/L1和7%.HCC组阳性率显著高于肝硬化组和健康对照组(分别P＜0.01);Ⅰ期和Ⅱ期HCC AFP-IgM阳性率(分别为89%和88%)高于Ⅲ期(30%,P＜0.05);AFP-IgM的水平与肿瘤分期、大小有关.结论 血清AFP-IgM对HCC的早期诊断具有重要意义,有望成为一个有用的辅助诊断HCC的生物标志.

abstractsObjective To investigate the expression level of AFP-IgM in hepatocellular carcinoma (HCC).Methods The serum AFP-IgM concentrations were detected by ELISA in 79 HCC patients,20 patients affected by liver cirrhosis and 30 healthy controls.Results AFP-IgM concentrations in serum and the positive rate were significantly higher in HCC than that in liver cirrhosis and in healthy controls(P＜0.01).The positive rates of AFP-IgM in the stage Ⅰ or Ⅱ(89%,88%)were higher than that of the stage Ⅲ(30%,P＜0.05).The serum concentration of AFP-IgM is related to the stage,tumor sizes.Conclusion AFP-IgM was of significance for early diagnosis of HCC,it will hopefully be a useful biological marker for the diagnosis of HCC.